SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-17-004145
Filing Date
2017-04-20
Accepted
2017-04-20 16:19:27
Documents
8
Period of Report
2017-05-17
Effectiveness Date
2017-04-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A mirati2017proxy.htm DEF 14A 833045
2 g368600a02.jpg GRAPHIC 3453
3 g368600a05.jpg GRAPHIC 14621
4 g641197a05.jpg GRAPHIC 8973
5 g775045a06.jpg GRAPHIC 11606
6 g775045a08.jpg GRAPHIC 11606
7 votingcardpage1a01.jpg GRAPHIC 119676
8 votingcardpage2a01.jpg GRAPHIC 87705
  Complete submission text file 0001628280-17-004145.txt   1173457
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35921 | Film No.: 17773232
SIC: 2834 Pharmaceutical Preparations